Introduction
Mantle cell lymphoma (MCL) is a mature B-cell NHL that is typically disseminated at diagnosis, involves the lymphoid tissues, gastrointestinal tract, and bone marrow, and in 20-30% of patients presents with leukemic disease. 1 MCL patients typically respond to conventional firstline chemoimmunotherapy regimens but most patients relapse within a few years. 2 Thus MCL has a relatively short median overall survival of 5-7 years, which is amongst the shortest of all B-cell lymphomas. 3 Bortezomib (Velcade™), the first proteasome inhibitor to reach the clinic, was approved by the US Food and Drug Administration as second-line treatment for MCL. 4 Bortezomib has a response rate of 30-50% in relapsed disease and was equally effective in patients who were sensitive or refractory to prior therapy. [5] [6] [7] Onset of response is fast, with a median time to response of only four weeks. 8 Bortezomib is also highly active as a single agent in Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia, and systemic AL amyloidosis. 4 Bortezomib is a reversible inhibitor of the proteasome, the major pathway for intracellular protein degradation. Bortezomib preferentially targets the chymotrypsin-like activity of the β5 subunit and to a lesser extent inhibits the caspase-like activity of the β1 subunit. 4 Proteasome inhibition results in stabilization of key proteins involved in cell cycle control, DNA replication and repair, and cell survival. Whether an effect on any specific protein or pathway is responsible for bortezomib cytotoxicity remains unresolved. 9 Inhibition of NF-κB signaling through stabilization of the cytoplasmic inhibitor of NF-κB (IκB) was initially thought to be a major mechanism of bortezomib action. However, recent studies in MCL and MM cells do not support this hypothesis, 10, 11 and in some settings bortezomib may actually increase NF-κB activity. 10, 12 On a more general level, proteasome inhibition disrupts protein homeostasis in both cytoplasm and the endoplasmic reticulum (ER). Bortezomib thus can elicit ER stress [13] [14] [15] that triggers a homeostatic response termed the unfolded protein response (UPR). The UPR orchestrates a complex transcriptional program in order to alleviate ER stress and restore protein homeostasis. 16, 17 Three ER-resident regulatory switches control the UPR leading to increased expression of proteins involved in ER biogenesis and capacity, redox pathways, and protein folding. ER stress activates an ER-membrane bound protein kinase IRE1 to splice XBP1 mRNA, to produces a key transcription factor of ER biogenesis. In addition, ATF6, an ERanchored transcription factor, is cleaved and translocates to the nucleus. These two transcription factors regulate ER-resident proteins, chaperones, and protein transporters thereby building the capacity to deal with protein load. The third UPR switch is PERK, an ERresident kinase that phosphorylates eIF2α leading to reduced protein synthesis while increasing
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Author Manuscript Published OnlineFirst on June 28, 2011; DOI: 10.1158/1078-0432.CCR- the translation of select mRNAs in particular of the transcription factor ATF4. 17 Failure to restore ER homeostasis ultimately leads to cell death. 18 Several effectors of UPR-mediated cell death have been identified and include caspase-4, 19 CHOP, 20 and the BH3-only proteins BIM 21 and NOXA. 22 Proteasome inhibition has also been reported to lead to oxidative stress. 13, [22] [23] [24] This effect is not unique to bortezomib but rather appears to be a consequence of the accumulation of misfolded proteins that would normally be degraded through the proteasome. 19, 25 The ensuing attempts at protein folding generate high levels of reactive oxygen species (ROS).
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Given that ROS scavengers protect from and depletion of glutathione increases bortezomibinduced cell death in vitro, it is apparent that ROS contribute to the cytotoxic effect of bortezomib. 22, 26, 27 Oxidative stress activates transcription of genes containing the so called antioxidant response element (ARE). 28 A key regulator of this oxidative stress response is the transcription factor NRF2, which in unstressed cells is sequestered in the cytoplasm by the adaptor protein KEAP1. 29 KEAP1 can be oxidized by ROS resulting in conformational changes that release NRF2. In addition, the UPR transducer PERK phosphorylates a threonine residue in the KEAP1 binding domain of NRF2 leading to its dissociation from KEAP1 and nuclear translocation. 30 Bortezomib inhibits proteasome activity in all cells but its clinical activity is limited to a few select malignancies. 4, 9 Likewise, activation of the UPR and/or generation of ROS have been We chose gene expression profiling to systematically study the effect of proteasome inhibition on the tumor biology of MCL in vitro and in patients during treatment. We hypothesized that resistant tumors would show preferential upregulation of homeostatic responses enabling them to withstand proteasome inhibition. Surprisingly, we found the opposite: in response to proteasome inhibition sensitive tumors showed strong upregulation of NRF2 target genes, of proteasome components, and protein ubiquitination gene expression programs, whereas resistant cells showed minimal gene expression changes. Furthermore, we discovered that increased expression of NRF2 target genes at baseline correlated with decreased sensitivity to proteasome inhibition.
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Materials and Methods

Cell lines and Patient samples
The mantle cell lymphoma (MCL) cell lines HBL-2, Jeko-1, JVM-2, Mino, NCEB-1, REC-1, SP-53, UPN1, and Z-138 were grown in RPMI 1640 (Cellgro, Herndon, VA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT), 2 mM L-glutamine, 100 units/ml of penicillin G and 100 mg/ml of streptomycin (Gibco, Long Island, NY) as previously reported. 31 Granta-519 cell line was grown in Dulbecco's modified Eagle's medium instead of RPMI (Cellgro).
Peripheral blood samples from five previously untreated patients with leukemic disease, who were treated on clinical studies at the NCI were collected before (0 hours), at 6 and 24 hours after the first and at 24 hours after the second injection of bortezomib ( normal B-cells) were purified by magnetic activated cell sorting using CD19 microbeads (Miltenyi, Auburn, CA). CD19 + cells were aliquoted and stored as pellets at -80 °C.
Gene expression profiling
Total RNA of CD19-selected tumor cells was isolated using Qiagen RNA isolation kit 
Data analysis
Research. Gene set enrichment analysis (v2.0) was performed using curated (C2) and motif (C3) gene sets from the Molecular Signature Database (v2.5; Broad Institute, Cambridge, MA). Gene sets were identified using a false discovery rate (FDR) of <0.1 (except for analysis of curated gene sets on MCL patients where a FDR of <0.2 was used), and a normalized enrichment score (NES) of >1.8 or <-1.8. Gene sets were ranked by NES. The leading edge genes, i.e. the genes that contribute most to the identification of the corresponding gene set, were averaged to a score that was used as a comparative measure of expression. Ingenuity Pathway Analysis was performed using the Benjamini-Hochberg method for multiple testing correction and a cutoff of FDR<0.05 was used (Ingenuity Systems ® ). Probesets identified were collapsed to genes by maximum expression value. Signaling pathways identified must contain at least three genes.
Gene expression data were visualized using Cluster (v2.11) and TreeView (v1.6) (Eisen laboratory, Stanford, CA). Statistical significance was assessed by Mann-Whitney nonparametric U test using Prism 4 software (v4, GraphPad Software Inc, La Jolla, CA) or Student's T-test as indicated in the figure legends.
Protein extraction and Immunoblot analysis
Preparation of whole cell extracts was performed as described previously. 31 Briefly, pelleted 
Polymerase chain reaction (PCR) for detection of XBP1 splicing
PCR analysis was performed to detect splicing of XBP1 using the following primers: forward 5'-TTACGAGAGAAAACTCATGGC-3' and reverse 5'-GGGTCCAAGTTGTCCAGAATGC-3'. 32 GAPDH primers were as follows: forward 5'-CCTGTTCGACAGTCAGCCG-3' and reverse 5'-CGACCAAATCCGTTGACTCC-3'. 30 cycles were performed at 95 °C for 45 sec, 58 °C for 30 sec and 72 °C for 20 sec. PCR products were separated using a 2.5% agarose gel and imaged using ChemiImager 5500 (Alpha Innotech Cell Biosciences, Santa Clara, CA) and AlphaEase Software (v3.2.2).
Cell survival (MTT) assay
5×10
4 cells per well were exposed to serial doubling concentrations of hydrogen peroxide (Sigma) for 24 hours in 96-well plates. 0.5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) reagent (Chemicon, Temecula, CA) was added 4 hours before the reaction was terminated by the addition of 0.01M HCl, 10% SDS. Absorbance was measured at the wavelengths of 570 nm (test) and 650 nm (reference) after overnight incubation.
Flow cytometry
To detect cell viability by flow cytometry, MitoTracker Green FM and MitoTracker Red CMX Ros were used (Invitrogen). Briefly, cells were incubated in media with 100 nM of each probe for 30 min at 37 °C, and 10,000 cells per tube were analyzed for data acquisition. To detect changes in mitochondrial transmembrane potential cells were stained with 20 nM 3,3-diexyloxacarbocyanine iodide (DiOC6 [3] ; Invitrogen) and the generation of reactive oxygen species was determined by staining cells with 2 μM dihydroethidine (Invitrogen) as described elsewhere.
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Results
Bortezomib induces a transcriptional response in MCL cell lines
We have previously characterized mantle cell lymphoma (MCL) cell lines in regards to bortezomib sensitivity. 31 A cutoff of 10 nM bortezomib was established to divide MCL cell lines into sensitive and resistant groups. Baseline proteasome activity and inhibition of the chymotrypsin-like activity by bortezomib was comparable between the two groups. 31 As it is now well established that proteasome inhibition triggers a complex cellular response activating both pro-and anti-apoptotic pathways, we hypothesized that differences in the cellular stress response to proteasome inhibition could explain differential drug sensitivity. Specifically, we wished to test whether induction of a protective response could give rise to bortezomib resistance. To this end, we used gene expression profiling to characterize the stress response To better understand the biologic basis of this response we submitted all genes that changed significantly in response to bortezomib to Ingenuity Pathway Analysis. In the sensitive cell lines we identified 3 pathways induced by bortezomib, most prominently the protein ubiquitination and the NRF2-mediated oxidative stress response pathways (P<0.0001; Figure   1D ). Twelve signaling pathways were found to be downregulated, most prominently the antigen presentation pathway (P<0.0001). Contrary to our initial hypothesis, no distinct pathways were identified among genes that changed in the resistant cell lines. Thus, bortezomib induced a transcriptional response involving protein ubiquitination and oxidative stress response pathways that was activated only in sensitive cells.
Bortezomib induces oxidative and ER-stress response pathways in vitro
To further dissect the transcriptional response we performed gene set enrichment analysis on bortezomib-induced gene expression changes (Supplemental Table 1 and 2). Several gene sets controlled by specific transcription factors were strongly upregulated in sensitive but less so in resistant cell lines (Figure 2A ). Biologic functions controlled by these transcription factors involve the response to oxidative stress (NRF2, NFE2, TCF11_MAFG, and BACH2), the UPR (NRF2 and XBP1), and heat shock (HSF and HSF1). The only gene sets significantly downregulated by bortezomib relate to cell cycle and are controlled by E2F transcription factors (Supplemental Table 1 ).
Next we interrogated bortezomib-induced gene expression changes relative to the activity of signaling pathways and the effects of chemical and genetic perturbations on cell biology. We again identified gene sets indicating an oxidative stress response including genes upregulated by H 2 0 2 in breast cancer cell lines and genes in the ARE-NRF2 pathway. We also observed downregulation of genes whose expression is known to be suppressed by oxidizing agents ( Figure 2B and Supplemental Table 2 ). In addition, two gene sets of the proteasome pathway were upregulated. Thus, this independent analysis using gene set enrichment analysis confirmed the key pathways identified by Ingenuity Pathway Analysis. Most gene sets linked to cell proliferation were downregulated in good agreement with the reduced expression of E2F-controlled genes (Supplemental Table 2 ) and reflects decreased proliferation of bortezomibtreated cells in agreement with reports that it can induce cell cycle arrest. 33, 34 Changes in expression of these gene sets were again more striking in sensitive than in resistant cell lines ( Figure 2B ). In the oxidative stress pathway the transcription factor NRF2 regulates numerous detoxifying and antioxidant genes. 35 Li and colleagues established a specific NRF2 signature in a genetic mouse model. 36 To compare the NRF2 response between different cell lines we derived an expression average of the NRF2 signature genes, which increased 15-fold in response to bortezomib in sensitive but only 2-fold in resistant cell lines (P<0.0063; Figure 2C and D). 
bortezomib-induced apoptosis ( Figure 3B ). Next we measured production of reactive oxygen species (ROS) in response to bortezomib in two sensitive and two resistant cell lines.
Bortezomib caused a striking increase in ROS production as measured with dihydroethidium in the sensitive cell lines. The increase in ROS was paralleled by a decrease in mitochondrial membrane potential indicating cell death. In contrast, resistant cell lines showed only minimal increase in ROS and little or no cell death ( Figure 3C ). The time-dependent increase in ROS production and its correlation with bortezomib sensitivity are in agreement with the strong induction of an NRF2 signature in sensitive cell lines. Finally, to directly assess the response to oxidative stress these four cell lines were treated with hydrogen peroxide and viability was analyzed by MTT assay. Again, bortezomib resistant cell lines were less affected by oxidative stress than sensitive cell lines ( Figure 3D ).
Bortezomib-induced transcriptional response in vivo
We wished to assess whether a stress response similar to that what we have defined in our model in vitro is also involved in the antitumor activity of bortezomib in MCL patients. We were genes that showed at least a 2-fold change on days 2 or 5 compared to pre-treatment in at least one of the five patients. Unsupervised hierarchical clustering grouped samples in good accordance with the therapeutic effect of bortezomib ( Figure 4B ).
For subsequent analyses we considered the two groups of samples identified by hierarchical clustering separately. Between both groups a total of 246 genes showed at least a 2-fold change, 240 of these were unique to MCL1 and MCL3, five were only identified in the MCL2, MCL4, MCL5 group, and one gene was found in both ( Figure 4B Figure 5D ). Finally, we aimed to identify genes differentially expressed between sensitive and resistant tumors at baseline. Twenty-six genes were more highly expressed in MCL1 and MCL3 compared to 75 genes whose expression was higher in MCL2, MCL4, and MCL5 ( Figure 6A 
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The BH3-only protein NOXA is induced in response to bortezomib in many cell types in vitro. Here, we show for the first time NOXA upregulation in primary tumor cells in MCL patients undergoing treatment with bortezomib. In keeping with its function as a terminal effector of bortezomib cytotoxicity, 22, 31 NOXA was upregulated only in cells that also demonstrated a stress response by gene expression profiling. While originally described as a p53 target gene, p53 is not necessary for NOXA induction in response to proteasome inhibition. 22 Recently, Wang and colleagues demonstrated an alternative pathway of NOXA activation involving epigenetic modification of the promoter combined with transcriptional activation by ATF3 and ATF4 dimerization. 15 As predicted by these studies, we found ATF3 and ATF4 upregulation in sensitive but not in resistant cells. Whereas ATF3 mRNA increased as part of the bortezomibinduced transcriptional response, ATF4 mRNA was largely unchanged, in keeping with its regulation through a translational mechanism downstream of PERK.
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For many cell types disruption of protein and ER homeostasis has been linked to induction of the UPR and bortezomib-induced cytotoxicity in vitro. 18 This effect may be particularly important in secretory cells and has been proposed as an explanation for the high sensitivity of plasma cells to proteasome inhibition. 4, 14 In vitro we observed bortezomib-induced upregulation
Research. This was confirmed by the demonstration of IRE1 phosphorylation, XBP1 splicing, and increased protein levels of ATF4 in bortezomib-treated cell lines. In contrast, in vivo we observed primarily an NRF2 gene expression response and no activation of the IRE1/XBP1 arm of the UPR. Thus, while bortezomib induces both UPR and oxidative stress responses in vitro, our results suggest that in vivo oxidative stress may dominate, at least in some settings. Given that UPR and oxidative stress response are modulated by several cellular factors including biosynthetic load, amino acid starvation, and redox homeostasis, 38 all of which can differ significantly between in vitro and in vivo environments, such differences are certainly plausible.
It is also notable that proteasome inhibition with bortezomib consistently induces NOXA but not BIM, 22, 31 whereas the apoptotic response of the UPR in response to classic pharmacologic or pathophysiologic ER stressors has been associated with BIM upregulation. 21 Taken together, these data indicate that bortezomib-induced cytotoxicity differs in several aspects from classic UPR-associated mechanisms.
We found a prominent antioxidant response in response to bortezomib both in vitro and in vivo. Oxidative stress is closely linked with ER stress. On one hand, ROS induce protein modifications that may lead to disruption of protein homeostasis and increased demands on protein degradation, on the other hand protein folding is one of the major sources of intracellular ROS. 19, 25 ER and oxidative stress also overlap in the activation of NRF2; ROS directly inactivate KEAP1, which binds and sequesters NRF2 in the cytoplasm, while PERK-mediated phosphorylation of NRF2 inhibits KEAP1 binding. 37 Inhibition of KEAP1 binding stabilizes NRF2
and allows its translocation to the nucleus, where it regulates genes involved in detoxification, redox homeostasis, and proteome maintenance. NRF2 thereby promotes cellular homeostasis in the face of oxidative and ER stress. In vitro, bortezomib increased ROS levels significantly in sensitive cells, but only minimally in resistant cells. We were unable to show a bortezomibdependent increase in ROS in primary tumor cells because fresh cells were not prospectively analyzed for ROS and the freeze-thaw process in DMSO interfered with the analysis. However, we detected increased NRF2 protein expression in tumor cells isolated directly from patients.
In cancer biology NRF2 has many at times even contradictory functions. of NRF2 against bortezomib-induced cytotoxicity a genome wide RNAi screen in colon cancer identified knockdown of NRF2 as a synthetic lethal hit. 41 NRF2 expression has also been linked with in vitro sensitivity to other chemotherapeutic agents in solid tumor cell lines. 42, 43 Whether treatment resistance is due to the overall enhanced ability of cells to deal with toxic insults or one distinct NRF2 target gene is undefined. While NRF2 upregulates proteasome subunits, 44 we have previously shown that proteasome capacity and the degree of inhibition of the chymotrypsin-like activity by bortezomib does not differ between sensitive and resistant cells. 31 The basis for increased NRF2 activity in a subset of MCL is unclear but could reflect differences in cellular differentiation. We recently reported that partial plasma cell differentiation of MCL cells is associated with bortezomib resistance. 45 Given that increased expression of genes involved in protein folding and redox homeostasis are critical elements of plasma cell differentiation, 19, 25, 46 this could explain an increased ability to cope with oxidative stress and account for reduced sensitivity to bortezomib.
This study is limited to the analysis of patients with leukemic disease supported by analysis of cell line models. Our findings thus await confirmation in nodal disease, and in a larger group of patients. Nevertheless, we have made several novel observations that direct further studies.
The correlation of increased cellular antioxidant capacity with bortezomib resistance could yield predictive markers of treatment success and identifies avenues for synergistic treatment approaches. The relative contribution of NRF2 to bortezomib resistance, a possible proapoptotic role, and the mechanism of its upregulation in a subset of MCL require further study.
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